AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Mediwound Ltd (NASDAQ:MDWD)
14.24 USD
+0.040 0.282%Sponsored Reports
Loading...
| Previous Close (in USD) | 14.2 |
|---|---|
| Change | +0.040 0.282% |
| 52 W H/L (in USD) | 19.860/7.100 |
| EBITDA (in USD) | -14.763M |
| PE Ratio | -- |
| Volume | 69383 |
| Diluted Eps TTM | -0.75 |
| Total Assets (in USD) | 66.459M |
|---|---|
| Total Liabilities (in USD) | 27.187M |
| Revenue TTM (in USD) | 18.686M |
| Cash (in USD) | 12.033M |
| Market Cap (in USD) | 155.569 M |
| Revenue Per Share TTM | 2.073 |
| Gross Profit TTM (in USD) | 13.165M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Employees: 100
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Prof. Lior Rosenberg M.D. | Co-Founder & Medical Director | 1946 |
| 2. | Mr. Boaz Gur-Lavie CPA, M.B.A. | Chief Financial Officer | 1974 |
| 3. | Mr. Yaron Meyer Adv. | Exec. VP, Gen. Counsel & Corp. Sec. | 1979 |
| 4. | Dr. Ety Klinger | Chief R&D Officer | 1962 |
| 5. | Mr. Ofer Gonen B.Sc. | Chief Exec. Officer | 1973 |
| 6. | Mr. Tzvi Palash B.Sc., M.Sc. | Chief Operating Officer | 1957 |
| 7. | Mr. Stephen T. Wills CPA, CPA, MST | Exec. Director | 1957 |
| 8. | Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer | NA |
| 9. | Ms. Hani Luxenburg | Chief Financial Officer | 1973 |
| 10. | Mr. Ofer Gonen B.Sc. | Chief Executive Officer | 1973 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -19.521M | -13.524M | -9.276M | 2.066M | -5.665M |
| Minority Interest | - | - | - | - | - |
| Net Income | -19.599M | -13.551M | -9.601M | 3.718M | -1.057M |
| Selling General Administrative | 8.332M | 6.109M | 8.687M | 9.306M | 7.987M |
| Gross Profit | 13.165M | 8.771M | 7.545M | 19.94M | 1.313M |
| Reconciled Depreciation | 1.272M | 1.238M | 1.09M | 1.149M | 0.577M |
| Ebit | -8.345M | -11.221M | -8.84M | 4.493M | -3.96M |
| Ebitda | -9.331M | -9.983M | -7.75M | 5.642M | -3.383M |
| Depreciation And Amortization | -0.986M | 1.238M | 1.09M | 1.149M | 0.577M |
| Operating Income | -8.345M | -11.221M | -8.84M | 4.493M | -3.96M |
| Other Operating Expenses | 34.841M | 34.984M | 30.603M | 27.296M | 7.361M |
| Interest Expense | 8.918M | 0.903M | 0.832M | 0.925M | 0.892M |
| Tax Provision | 0.078M | 0.027M | - | - | - |
| Interest Income | 0.27M | 0.011M | 0.297M | 0.434M | 0.412M |
| Net Interest Income | -2.258M | -1.082M | -0.549M | -2.549M | -1.486M |
| Income Tax Expense | 0.078M | 0.027M | 0.325M | -1.652M | -9.689M |
| Total Revenue | 26.496M | 23.763M | 21.763M | 31.789M | 3.401M |
| Total Operating Expenses | 21.51M | 19.992M | 16.385M | 15.447M | 5.273M |
| Cost Of Revenue | 13.331M | 14.992M | 14.218M | 11.849M | 2.088M |
| Total Other Income Expense Net | -11.176M | -2.303M | -0.436M | -2.427M | 6.567M |
| Net Income From Continuing Ops | -19.599M | -13.551M | -9.276M | 2.066M | -5.665M |
| Net Income Applicable To Common Shares | -19.599M | -13.551M | -9.196M | 4.955M | -1.057M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 66.459M | 50.016M | 19.744M | 31.07M | 40.59M |
| Intangible Assets | 0.165M | 0.231M | 0.297M | 0.363M | 0.429M |
| Other Current Assets | 0.722M | 9.982M | 2.706M | 0.573M | 0.396M |
| Total Liab | 27.187M | 39.102M | 24.326M | 23.798M | 25.421M |
| Total Stockholder Equity | 31.595M | 10.914M | -4.582M | 7.272M | 15.169M |
| Other Current Liab | 4.916M | 6.338M | 2.408M | 1.75M | 0.569M |
| Common Stock | 0.184M | 0.143M | 0.075M | 0.075M | 0.075M |
| Capital Stock | 0.184M | 0.143M | 0.075M | 0.075M | 0.075M |
| Retained Earnings | -174.822M | -168.106M | -148.507M | -134.956M | -125.76M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.364M | 0.469M | - | 0.006M |
| Cash | 12.033M | 33.895M | 11.046M | 17.376M | 7.242M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 10.829M | 12.057M | 10.721M | 8.266M | 10.373M |
| Current Deferred Revenue | 0.024M | 0.063M | 0.543M | 0.462M | 0.249M |
| Net Debt | -5.322M | -33.049M | -9.655M | -15.635M | -5.236M |
| Short Term Debt | 0.361M | - | 3.077M | 3.062M | 5.488M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 6.711M | 0.846M | 1.391M | 1.741M | 2.006M |
| Other Stockholder Equity | 206.251M | 178.882M | 143.869M | 142.193M | 140.871M |
| Property Plant Equipment | - | 3.581M | 4.026M | 4.514M | 4.533M |
| Total Current Assets | 49.695M | 45.84M | 14.952M | 26.193M | 35.622M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 29.675M | - | 0M | 4.024M | 22.036M |
| Net Receivables | 4.419M | 9.525M | 2.706M | 3.229M | 4.551M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 2.846M | 1.963M | 1.2M | 1.38M | 1.613M |
| Accounts Payable | 5.528M | 5.656M | 4.693M | 2.992M | 4.067M |
| Accumulated Other Comprehensive Income | -0.018M | -0.005M | -0.019M | -0.04M | -0.017M |
| Non Currrent Assets Other | 0.183M | 0.364M | 0.469M | - | 0.006M |
| Non Current Assets Total | 16.764M | 4.176M | 4.792M | 4.877M | 4.968M |
| Capital Lease Obligations | 6.35M | 0.846M | 1.391M | 1.741M | 2.006M |
| Long Term Debt Total | - | - | - | - | 2.006M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.481M | 4.002M | 18.034M | -6.897M | -17.04M |
| Total Cashflows From Investing Activities | -0.481M | 3.548M | 17.385M | -6.897M | -17.04M |
| Total Cash From Financing Activities | 35.764M | -1.05M | -0.629M | -1.006M | 0.046M |
| Net Income | -19.599M | -13.551M | -9.196M | 4.955M | -1.057M |
| Change In Cash | 22.849M | -6.33M | 10.134M | 0.526M | -29.353M |
| Begin Period Cash Flow | 11.046M | 17.376M | 7.242M | 6.716M | 36.069M |
| End Period Cash Flow | 33.895M | 11.046M | 17.376M | 7.242M | 6.716M |
| Total Cash From Operating Activities | -11.885M | -8.916M | -6.895M | 8.289M | -12.154M |
| Depreciation | 1.272M | 1.238M | 1.09M | 1.149M | 0.577M |
| Other Cashflows From Investing Activities | 0.074M | 0.035M | 0.274M | -1.055M | 0.106M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -0.721M | 0.257M | 0.141M | 0.067M | 0.206M |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | -1.915M | -1.05M | -0.121M | -1.006M | 0.046M |
| Capital Expenditures | 0.555M | 0.489M | 0.923M | 0.792M | 0.534M |
| Change In Working Capital | -7.244M | 0.162M | -0.061M | 4.492M | -1.008M |
| Other Non Cash Items | 11.74M | 1.686M | 0.323M | -1.685M | -11.512M |
| Free Cash Flow | -12.44M | -9.405M | -7.818M | 7.497M | -12.688M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | EAM Ultra Micro Cap | 2 years ago | 43798 |
| 2. | Pleiades Small Cap Equity A | 2 years ago | 42884 |
| 3. | Yelin Lapidot Equity IL | 2 years ago | 30000 |
| 4. | 1290 Essex Small Cap Growth I | 2 years ago | 24889 |
| 5. | Meitav Sky Stocks IL | 2 years ago | 17183 |
| 6. | Meitav Sky Investments | 2 years ago | 14319 |
| 7. | iShares Micro-Cap ETF | 2 years ago | 12587 |
| 8. | Dolphin 90/10 IL | 2 years ago | 11500 |
| 9. | Yelin Lapidot Growth Equity IL | 2 years ago | 9348 |
| 10. | apo Emerging Health | 2 years ago | 9000 |
| 11. | I.B.I 70/30 | 2 years ago | 7287 |
| 12. | Bailard Micrcap Value | 2 years ago | 6900 |
| 13. | Nationwide Bailard Cogntv Val M | 2 years ago | 6900 |
| 14. | Bailard Small Cap Value | 2 years ago | 6900 |
| 15. | Fidelity Nasdaq Composite Index | 2 years ago | 5551 |
| 16. | Essex Inv Mgt Micro Cap Growth | 2 years ago | 3305 |
| 17. | Yelin Lapidot 75/25 Growth IL | 2 years ago | 2883 |
| 18. | Dolphin Flexible | 2 years ago | 2500 |
| 19. | Yelin Lapidot 80/20 Growth IL | 2 years ago | 2411 |
| 20. | Yelin Lapidot 90/10 Growth IL ! | 2 years ago | 2018 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Rosalind Advisors, Inc. | 2 years ago | 485990 |
| 2. | Dafna Capital Management LLC | 2 years ago | 257653 |
| 3. | Uniplan Investment Counsel, Inc. | 2 years ago | 145270 |
| 4. | Essex Investment Management Company, LLC | 2 years ago | 132487 |
| 5. | Wells Fargo & Co | 2 years ago | 132104 |
| 6. | Yelin Lapidot Holdings Management Ltd | 2 years ago | 125493 |
| 7. | Sargent Investment Group, LLC | 2 years ago | 124408 |
| 8. | Silverberg Bernstein Capital Management LLC | 2 years ago | 85184 |
| 9. | Renaissance Technologies Corp | 2 years ago | 55944 |
| 10. | Sphera Funds Management Ltd. | 2 years ago | 48980 |
| 11. | Legato Capital Management LLC | 2 years ago | 47801 |
| 12. | Meitav Dash Investments Ltd | 2 years ago | 31502 |
| 13. | Millennium Management LLC | 2 years ago | 28528 |
| 14. | We Are One Seven, LLC | 2 years ago | 12158 |
| 15. | BlackRock Inc | 2 years ago | 11442 |
| 16. | Pathstone Holdings LLC | 2 years ago | 10874 |
| 17. | Advisor Group Holdings, Inc. | 2 years ago | 5029 |
| 18. | PNC Financial Services Group Inc | 2 years ago | 4229 |
| 19. | Morgan Stanley - Brokerage Accounts | 2 years ago | 2808 |
| 20. | Advisory Services Network, LLC | 2 years ago | 143 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...